Articles tagged with: Older Patients
News»

Results of a recent retrospective analysis indicate that stem cell transplantation may be underutilized in multiple myeloma patients 80 years of age or older.
Researchers from the M. D. Anderson Cancer Center in Houston found that only 0.5 percent (9 patients) of the 1,740 multiple myeloma patients who received an autologous (own) stem cell transplant between January 2007 and June 2018 at their institution were 80 years or older at the time of their first transplant.
Yet the transplant outcomes seen in this small sample of patients were favorable, and the toxicity …
News»

Good morning, myeloma world.
We hope you had a pleasant weekend and that your new week is off to a good start.
The big news today is that Darzalex (daratumumab) has been approved in Europe as a new treatment for multiple myeloma. We will be publishing a separate news article on the approval, which was announced a few hours ago. In the meantime, you can find information about the approval in this press release from Genmab, the company that initially developed Darzalex.
The other news we have for you …
News»

Good morning, myeloma world.
It's been a very chilly morning here at Myeloma Morning Headquarters. After teasing us with summerlike temperatures the past few weeks, Mother Nature has decided she's not done with the part of the thermometer below freezing.
We'll be focusing on two new research studies in today's report.
The first study looks at outcomes of allogeneic (donor) stem cell transplantation for multiple myeloma. Using outcomes from a single U.S. treatment center, the study authors find that whether or not an allogeneic transplant patient had high-risk disease at diagnosis did …
News»

The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.
Previous years have witnessed research shedding new light on existing myeloma therapies, as well as additional research about potential new therapies.
But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic improvements in the treatment of the disease.
In 2013, not only was there more research about existing therapies, and more research about …
News»

One of the key presentations during the recent American Society of Hematology (ASH) annual meeting in New Orleans was one that summarized initial results of a large international Phase 3 clinical trial known as the "FIRST", or MM-020, trial.
The trial results show that continuous administration of Revlimid and dexamethasone improves response rates as well as progression-free and overall survival in newly diagnosed multiple myeloma patients who are older or not eligible for stem cell transplantation.
Specifically, the researchers found that the overall response rate was highest (75 percent) among patients who received …
News»

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of the oral …
News»

Findings from a recent retrospective study conducted by researchers at the Mayo Clinic show that overall survival for multiple myeloma patients treated at that cancer center has improved significantly between 2001 and 2010.
Patients diagnosed between 2001 and 2005 had a median overall survival of 4.6 years, while those diagnosed more recently – between 2006 and 2010 – had an improved median overall survival of 6.1 years, or almost one-third higher.
In addition, the share of patients dying within a year of diagnosis, known as early mortality, also decreased significantly during the 10-year time …